Munich, Germany-based Leukocare AG has appointed Andreas Seidl as chief operating officer and a member of the executive board to manage its technology platform for improving the stability and quality of biologics. Dr Seidl joins from the Sandoz unit of Novartis where he was head of global analytical characterisation and bioanalytics. During his time at Novartis he led the development of the first complex biosimilar, epoetin alfa, to be approved in Europe. Dr Seidl is a chemist by training and received his PhD from the University of Konstanz, Germany.
Leukocare announced the appointment on 25 March 2019.
Copyright 2019 Evernow Publishing